Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

Similar articles for PubMed (Select 23857916)

1.

Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.

Takahashi M, Goto T, Takita Y, Chung SK, Wang Y, Gau SS.

Asia Pac Psychiatry. 2014 Mar;6(1):62-70. doi: 10.1111/j.1758-5872.2012.00204.x. Epub 2012 Jul 23.

PMID:
23857916
2.

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.

J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.

PMID:
19142107
3.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
4.

Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.

Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D.

J Clin Psychiatry. 2005 Mar;66(3):294-9.

PMID:
15766294
5.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

6.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
7.

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.

J Clin Psychopharmacol. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23. Erratum in: J Clin Psychopharmacol. 2014 Aug;34(4):542-3.

PMID:
23277268
8.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
9.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
10.

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Simpson D, Plosker GL.

CNS Drugs. 2004;18(6):397-401. Review.

PMID:
15089111
11.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
12.

A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.

Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P.

J Child Adolesc Psychopharmacol. 2007 Aug;17(4):447-60.

PMID:
17822340
13.

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D.

J Atten Disord. 2008 Nov;12(3):248-53. doi: 10.1177/1087054708316250. Epub 2008 Apr 30.

PMID:
18448861
14.

A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.

Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P.

Pharmacopsychiatry. 2012 May;45(3):100-7. doi: 10.1055/s-0031-1291319. Epub 2011 Dec 15.

PMID:
22174029
15.

Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.

Lee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW, Park TW, Yook KH, Lee JI, Bahn GH, Hirata Y, Goto T, Takita Y, Takahashi M, Lee S, Treuer T.

Asia Pac Psychiatry. 2014 Dec;6(4):386-96. doi: 10.1111/appy.12160. Epub 2014 Oct 27.

PMID:
25345739
16.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.

Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.

Depress Anxiety. 2009;26(3):212-21. doi: 10.1002/da.20549.

PMID:
19194995
17.

Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.

Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.

Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27.

PMID:
22285724
18.

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

Adler L, Dietrich A, Reimherr FW, Taylor LV, Sutton VK, Bakken R, Allen AJ, Kelsey D.

Ann Clin Psychiatry. 2006 Apr-Jun;18(2):107-13.

PMID:
16754416
19.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
20.

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ.

J Am Acad Child Adolesc Psychiatry. 2005 Jul;44(7):647-55.

PMID:
15968233
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk